武梦超

Cooley advised Asymchem Laboratories, a contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its HK$7.15 billion (US$916 million) initial public offering – marking the largest healthcare IPO in Hong Kong this year – of 18,415,400 H shares, which now trade on the Hong Kong Stock Exchange. Partners Yiming Liu and Michael Yu led the Cooley team advising Asymchem.

Cooley advised the joint sponsors and underwriters on ecommerce company Huitongda’s HK$2.2 billion (US$285 million) initial public offering of 51,606,200 H shares on the Hong Kong Stock Exchange, subject to the exercise of the underwriters’ option to purchase an additional 7,740,900 H shares. Partners Michael Yu and Will Cai led the Cooley team advising the joint sponsors and underwriters.

Cooley advised the underwriters for Fenbi, an internet-born test preparation company, on its proposed listing of shares on the Main Board of the Stock Exchange of Hong Kong Limited. Partners Ethan Jin, Michael Yu and Will Cai led the Cooley team.

Cooley advised the underwriters of Zhejiang Taimei Medical Technology (Taimei), a digital solution provider focused on the pharmaceutical and medical device industry in China, on its HK$335.1 million initial public offering.